Differences in Immune Response between HCV Positive, HIV Negative Haemophilia A and B Patients

Summary

We measured numbers of lymphocytes and subsets in seven HIV negative, HCV positive severe haemophilia B patients, before and after substitution was changed from prothrombin complex concentrate to monoclonally purified concentrate. Data were compared with controls and our previous findings in haemophilia A.

At baseline, haemophilia B patients did not differ from controls. After two years, T helper cells showed an increase (p = 0.028), while a rise in B cells approached statistical significance (p = 0.063). Haemophilia A patients showed increased numbers of activated non-B lymphocytes (p = 0.003) and lowered numbers of B cells (p = 0.001) at baseline. After two years activated non-B lymphocytes decreased (p = 0.004), as did the CD4/CD8 ratio (p = 0.002), due to increasing numbers of CD8 positive cells (p = 0.087).

Our data suggest minor inhibition of the immune system in haemophilia B patients, which recovers after changing therapy to a monoclonally purified product. These findings contrast with the excessive immune stimulation in haemophilia A. The observed differences might be due to the administered concentrates.

• References

• 1 Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy. B J Haematol 1992; 80: 364-9.
• 2 Carr R, Veitch SE, Edmond E, Peutherer JF, Prescott RJ, Steel CM, Ludlam CA. Abnormalities of circulating lymphocyte subsets in haemophiliacs in an AIDS-free population. Lancet 1984; 1 8392 1431-4.
• 3 Smid WM, Van der Meer J, Smit JW, Halie MR. The course of pre-existent immune abnormalities in HIV negative haemophliacs treated for two years with a monoclonal purified factor VIII concentrate. Thromb Haemost 1993; 69 (04) 306-10.
• 4 Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-ß as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021-30.
• 5 Eibl MM, Ahmad R, Wolf HM, Linnau Y, Götz E, Mannhalter JW. A com ponent of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions. Blood 1987; 69 (04) 1153-60.
• 6 Lee CA, Kernoff PBA, Karayiannis P, Waters J, Thomas HC. Abnormal T-lymphocyte subsets in hemophilia: relation to HLA proteins in plasma products. N Engl J Med 1984; 310: 1058.
• 7 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387-91.
• 8 Wadsworth C, Blombäck M, Kjellman H, Hanson LÅ. Complexes of IgG and plasma proteins in factor VIII preparations – a possible cause of adverse reactions. Vox Sang 1985; 49: 319-22.
• 9 Pejaudier L, Kichenin-Martin V, Boffa MC, Steinbuch M. Appraisal of the protein composition of prothrombin complex concentrates of different origins. Vox Sang 1987; 52: 1-9.
• 10 Prince HE, Fang CT. Unaltered lymphocyte subsets in hepatitis C virus-seropositive blood donors. Transfusion 1992; 32 (02) 166-8.